Trial Outcomes & Findings for Clinical Evaluation of a Daily Disposable Contact Lens in Symptomatic Weekly/Monthly Lens Wearers (NCT NCT01614600)

NCT ID: NCT01614600

Last Updated: 2013-12-04

Results Overview

Contact lens symptoms were evaluated using the Contact Lens Dry Eye Questionnaire (CLDEQ). Subjects rated 8 common contact lens-related ocular surface dryness symptoms at Baseline, Week 1, and Week 2 using a 5-point scale (1=never or not at all intense, 5=constantly or very intense). A scoring algorithm was used to calculate a composite score for each visit for all symptoms (-6.5 to 10). A higher composite score would indicate more contact lens related dry eye and a lower score, less contact lens related dry eye.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

88 participants

Primary outcome timeframe

Baseline, Week 1, Week 2

Results posted on

2013-12-04

Participant Flow

Participants were recruited from 8 study centers located in the United States.

Of the 91 participants enrolled, 3 were exited as screen failures prior to dispensing of the study product. This reporting group includes all enrolled and dispensed participants.

Participant milestones

Participant milestones
Measure
DAILIES® AquaComfort Plus®
Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
Overall Study
STARTED
88
Overall Study
COMPLETED
84
Overall Study
NOT COMPLETED
4

Reasons for withdrawal

Reasons for withdrawal
Measure
DAILIES® AquaComfort Plus®
Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
Overall Study
Unacceptable fit
1
Overall Study
Discomfort
1
Overall Study
Unable to remove lens at the end of day
1
Overall Study
Protocol deviation
1

Baseline Characteristics

Clinical Evaluation of a Daily Disposable Contact Lens in Symptomatic Weekly/Monthly Lens Wearers

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
DAILIES® AquaComfort Plus®
n=88 Participants
Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
Age Continuous
32.2 years
STANDARD_DEVIATION 9.0 • n=5 Participants
Sex: Female, Male
Female
66 Participants
n=5 Participants
Sex: Female, Male
Male
22 Participants
n=5 Participants
Region of Enrollment
United States
88 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline, Week 1, Week 2

Population: Per Protocol: All enrolled and dispensed participants, minus any major protocol deviators as determined by masked review.

Contact lens symptoms were evaluated using the Contact Lens Dry Eye Questionnaire (CLDEQ). Subjects rated 8 common contact lens-related ocular surface dryness symptoms at Baseline, Week 1, and Week 2 using a 5-point scale (1=never or not at all intense, 5=constantly or very intense). A scoring algorithm was used to calculate a composite score for each visit for all symptoms (-6.5 to 10). A higher composite score would indicate more contact lens related dry eye and a lower score, less contact lens related dry eye.

Outcome measures

Outcome measures
Measure
DAILIES® AquaComfort Plus®
n=74 Participants
Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
Mean Change From Baseline in Contact Lens-Related Dryness Symptoms at Week 1 and Week 2
Change from Baseline at Week 1
-0.09 Units on a scale
Standard Deviation 1.24
Mean Change From Baseline in Contact Lens-Related Dryness Symptoms at Week 1 and Week 2
Change from Baseline at Week 2
-0.29 Units on a scale
Standard Deviation 1.06

Adverse Events

DAILIES® AquaComfort Plus®

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jami Kern, MBA, PhD

Alcon Research, Ltd.

Phone: 1-888-451-3937

Results disclosure agreements

  • Principal investigator is a sponsor employee Sponsor reserves the right of prior review of any publication or presentation of information related to the study.
  • Publication restrictions are in place

Restriction type: OTHER